Contraception
Volume 79, Issue 6 , Pages 463-468, June 2009

Duet® for menstrual protection: a feasibility study in Zimbabwe☆

  • Sarah Averbach

      Affiliations

    • Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA 94107, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Nuriye Sahin-Hodoglugil

      Affiliations

    • Women's Global Health Imperative, RTI International, San Francisco, CA 94104, USA
    • ,
  • Petina Musara

      Affiliations

    • University of Zimbabwe-University of California San Francisco Research Collaborative Programme in Women's Health, Harare, Zimbabwe
    • ,
  • Tsungai Chipato

      Affiliations

    • University of Zimbabwe-University of California San Francisco Research Collaborative Programme in Women's Health, Harare, Zimbabwe
    • ,
  • Ariane van der Straten

      Affiliations

    • Women's Global Health Imperative, RTI International, San Francisco, CA 94104, USA
    • Department of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA 94105, USA

Received 30 September 2008; received in revised form 10 December 2008; accepted 10 December 2008. published online 29 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was funded by Reprotect, Inc. (contract # P0015330) when Drs. van der Straten and Sahin-Hodoglugil were at the Department of OBGYN, University of California San Francisco. Sarah Averbach was a Doris Duke Clinical Research Fellow/UCSF CTSI Fellow. The authors are not employed by, nor do they own equity in, Reprotect, Inc.

PII: S0010-7824(08)00551-9

doi:10.1016/j.contraception.2008.12.002

Contraception
Volume 79, Issue 6 , Pages 463-468, June 2009

Article Tools

* Image Usage & Resolution